How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies | Zendy

Antoni Ribas | Zendy; Madhav V. Dhodapkar | Zendy; Katie M. Campbell | Zendy; Faith E. Davies | Zendy; Steven D. Gore | Zendy; Ronald Levy | Zendy; Lee M. Greenberger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies

Author(s) -

Antoni Ribas,

Madhav V. Dhodapkar,

Katie M. Campbell,

Faith E. Davies,

Steven D. Gore,

Ronald Levy,

Lee M. Greenberger

Publication year - 2021

Publication title -

blood cancer discovery

Language(s) - English

Resource type - Journals

eISSN - 2643-3249

pISSN - 2643-3230

DOI - 10.1158/2643-3230.bcd-21-0166

Subject(s) - covid-19 , medicine , vaccination , immunization , immunology , antibody , intensive care medicine , virology , outbreak , disease , infectious disease (medical specialty)

Summary: Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research